Skip to content

Author

Hao-Hui Fang

We have 2 of 9 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Final Analysis of the Neotorch Study: Perioperative Toripalimab in Combination with Chemotherapy for Patients with Stage Ⅱ/Ⅲ Resectable Non-Small Cell Lung Cancer.

BACKGROUND Interim analysis of the Neotorch study demonstrated significant benefit in event-free survival (EFS) and major pathological response (MPR) rate for perioperative toripalimab plus chemotherapy in patients with resectable Stage Ⅲ non-small cell lung cancer (NSCLC). Here, we report the final analysis results of...

Zi-Ming Li, L. Wu, W.-X. Wang et al. · 0 citations
Clinical trial Open access Aug 2026

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib demonstrated superior efficacy to gefitinib with a similar tolerability profile in the first-line treatment of EGFR-mutated advanced NSCLC with common and uncommon EGFR-activating mutations.

Jia Yu, Anwen Xiong, Qi-Ming Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.